This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
With offices in Dallas, Houston, and Austin, GPG Ventures invests nationally in biotech, digital health, medtech, consumer health, and general B2B tech. Individual and family office LPs have invested alongside the firm’s partners in more than 100 portfolio companies since 2011.
Financing the Future of Digital Medicine Digital healthcare investments are benefiting from the surfeit of cash that is lifting the biotech sector and, in fact, all industries in 2018. Learn more by downloading the report. EBD Group “The Nutrino team is passionate about personalized nutrition data services and technologies.
And so I’m stoked to see it all come together beginning with the first Health SXSW in 2011. Advancements in biotech promise to transcend human limitations and end disability as we know it; from optogenetic interfaces with the human nervous system to synthetic appendages that move and feel like biological counterparts! So here we go.
There’s a lot of hype,” Novorol says; a whole lot more than when she began building an AI-focused business back in 2011. As a result, more and more investors are paying attention to the health sector which, due to its complexity, has traditionally been left to biotech or medical devices investors. And that’s a double-edged sword.
By 2011, having moved from Brooklyn to Los Angeles, they began educating themselves about the medical research business, searching for a diabetes documentary project, and talking with medical researchers and people with diabetes who might be willing to come in front of their cameras.
By 2011, having moved from Brooklyn to Los Angeles, they began educating themselves about the medical research business, searching for a diabetes documentary project, and talking with medical researchers and people with diabetes who might be willing to come in front of their cameras.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content